Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Sunitinib in High-Risk Stage III ccRCC Based on CpG Methylation Assay
NCT02688491Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jul 2016
- Primary completion
- Jul 2026
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) comparing Sunitinib with Observation (2 arms). Primary endpoint: Disease Free Survival at 10 years. Planned start Jul 2016; status: not yet recruiting.
02
Drugs
sunitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02688491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688491.